The importance of these co-existing mutations has been previously discussed in the CGP report[7], where enhanced sensitivity to ERBB2/EGFR targeting agents appears to be related to elevated EGFR expression in tumor cells with SMAD4_MUT. Here, EGFR is linked to neoplasm.